Ageing does not impact drug-drug interaction magnitudes with antiretrovirals. AIDS
Stader et al. aimed to investigate the impact of ageing on drug–drug interactions (DDI) magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir.
This was a prospective clinical study including people living with HIV (PLWH) aged at least 55 years in Lausanne and Basel enrolled in the Swiss HIV Cohort Study receiving amlodipine, atorvastatin and/or rosuvastatin with a dolutegravir or a boosted darunavir-containing regimen. A total of 21 white PLWH (four women) aged 56–80 years were included in the study. The mean and standard deviation (SD) of the area under the curve (AUC) were calculated for the comedications received with either dolutegravir or boosted darunavir.
The obtained AUC ratios in ageing PLWH were in the same range as DDI magnitudes reported in young individuals aged 20–50 years, thus, demonstrating that ageing has a marginal impact on DDI magnitudes.
In conclusion, the clinically observed data demonstrate that DDI magnitudes between ARVs and comedications appear to be similar in ageing PLWH compared with young individuals and thus, the clinical management of DDIs can be similar. Further research is warranted in the future to investigate more DDI scenarios with a larger study population including more women to further support the clinical management of DDIs in ageing PLWH.